Daily Bio News Summary — 2026-09-27: A quiet Sunday with three regulatory signals and a five-year CAR-T readout

A Sunday harvest produced seven items from three free sources: Pharmaphorum (3), BioSpace (1) and the PR Newswire FDA approval feed (3), published between Sept. 22 and Sept. 25. The batch divides cleanly into two halves — four regulatory and clinical items on the drug-development side, and three device-side milestones. Only the harvested frontmatter is cited below; where a headline or deck carries a specific figure, that figure is quoted as the source framed it.

Regulatory decisions and review milestones

Neuraxpharm and Minoryx secured what Pharmaphorum describes as the first approved drug therapy in the European Union for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease. Nezglyal’s clearance is the kind of asset-level milestone that rarely produces a large headline but resets the treatment pathway for a disease with almost no options. It is also a reminder that most “first approval” events in 2026 are happening outside the United States (Pharmaphorum, 2026-09-25).

On the U.S. side, the FDA has started a speedy review of a new bladder cancer indication for AstraZeneca’s Imfinzi — framed by the source as a move that could help the company “fend off encroachment from MSD’s Keytruda” (Pharmaphorum, 2026-09-25). The competitive subtext matters more than the review itself: bladder cancer is one of the few remaining settings where a PD-1/PD-L1 franchise can still pick up a broad label without competing head-on with an already-embedded standard.

Clinical readouts

MSD’s return to ophthalmology produced its first win, with a positive phase 3 trial of the Wnt-targeted drug remigromig in diabetic macular oedema (Pharmaphorum, 2026-09-25). The EyeBio acquisition was the vehicle, and the readout is the first evidence that the deal bought a real late-stage asset rather than an early-stage option. DME is a crowded anti-VEGF market, so the strategic question shifts immediately to differentiation and pricing rather than to whether the mechanism works at all.

The day’s most substantial long-term data came from Johnson & Johnson and Legend Biotech: ten of twenty patients who received Carvykti remained alive at five years of follow-up in multiple myeloma (BioSpace, 2026-09-25). Five-year survival figures in a heavily pretreated myeloma population are the kind of datapoint that ends the “durability” argument for CAR-T in earlier lines of treatment — and they arrive as Legend navigates a leadership transition and a growing competitive field.

Device-side milestones

Three items on the device and diagnostics side filled out the batch:

• Marani Health received FDA 510(k) clearance for its M•care System (MW-20), including the M•wrap wearable. The company frames the clearance as the transition from development to commercialization, with the cleared system heading for commercial availability in 2027 and prescribed maternal monitoring moving from the clinic to the home (PR Newswire FDA, 2026-09-24).
• A peer-reviewed study in Spine Open reported two-year results from the U.S. Investigational Device Exemption trial of the Synergy Disc, finding higher composite clinical success, reduced neck and arm pain and greater patient satisfaction versus anterior cervical discectomy and fusion (PR Newswire FDA, 2026-09-24).
• BRIJ Medical published a 100-case clinical study of its Brijjit Force-Modulating Tissue Bridges for postoperative incision management in sports medicine, reporting zero documented wound complications across 100 consecutive outpatient procedures (PR Newswire FDA, 2026-09-22).

What this batch is NOT telling us

The regulars are absent. There is no deal news — no licensing pact, no acquisition, no IPO pricing — on a weekend where the week’s earlier cycle (Telix/ITM, Lilly/InnoCare, ADARx, Electra) has already been harvested. There is no AI-in-bio item and no China-specific story, both of which have appeared in nearly every batch over the past two weeks. There is also no pricing or policy story, and no clinical failure readout.

The thinness is partly structural: this is a Sunday, and two of the eleven sources are contributing nothing at all right now. BioPharma Dive parsed zero items for the fifth consecutive run and Reuters remains captcha-blocked. MedCity’s 14 candidates all arrived with a fallback date and every one was a duplicate or a contributor column. In practice today’s harvest was carried by three sources.

Reading order

1. Carvykti’s five-year follow-up — the only datapoint in the batch that changes a clinical argument.
2. MSD’s phase 3 eye win — first validation of the EyeBio acquisition, in a market where differentiation is the whole game.
3. cALD’s EU first — the rarest disease in the batch and the clearest example of EU-first approval flow.
4. Imfinzi’s speedy review — small on its own, but part of the PD-1 franchise endgame in bladder cancer.
5. Marani Health’s clearance — the most commercially legible of the device items.

How to read the underlying articles

Every item above maps to a markdown file in src/content/news/ whose sourceUrl field points at the original publisher page. The frontmatter is the complete record of what was harvested; nothing in this summary goes beyond those headlines and decks. Items that were paywalled, politically charged, older than 30 days, or duplicates of already-published coverage were excluded before writing and are not referenced here.

Today’s items

1. EU clears first drug therapy for rare disease cALD — Pharmaphorum, 2026-09-25
2. FDA starts speedy review of Imfinzi in bladder cancer — Pharmaphorum, 2026-09-25
3. Wnt drug gives MSD first eye disease win after EyeBio deal — Pharmaphorum, 2026-09-25
4. J&J, Legend tout long-term survival benefits for Carvykti in multiple myeloma — BioSpace, 2026-09-25
5. Marani Health receives FDA clearance for M•care System — PR Newswire FDA, 2026-09-24
6. Peer-reviewed study shows two-year outcomes for the Synergy Disc — PR Newswire FDA, 2026-09-24
7. 100 consecutive sports medicine cases, zero documented wound complications with Brijjit — PR Newswire FDA, 2026-09-22